Understanding silibinin's modes of action against HCV using viral kinetic modeling
about
HCV Kinetic Models and Their Implications in Drug DevelopmentViral kinetic modeling: state of the artSilymarin for HCV infectionA hepatitis C virus infection model with time-varying drug effectiveness: solution and analysisSmall molecule inhibitors of HCV replication from pomegranateAnalysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelSeverity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapyClinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft ReinfectionHepatitis C viral kinetics: the past, present, and future.Interplay between Hepatitis C Virus and Redox Cell Signaling.Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.How to optimize HCV therapy in genotype 2 patients.Modeling Viral Spread.Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other ClassesContinued value in understanding viral kinetic decline during interferon-free therapy for HCV.Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.
P2860
Q26801602-55742BDC-04B0-4216-A09C-83F13E2DF2E5Q26824655-F2CF252A-44A2-4868-BE51-8B2486D4163BQ26851453-12D4279D-9F93-4FBF-9A49-32199B695952Q28541682-8E94AB76-46BC-49D4-AE62-407F433EA9E9Q33794802-E4413D7A-6F04-4030-B4BE-606E01FFFFE8Q34334375-669BA978-7BBB-417A-8DEB-9423A1443C88Q34675037-D18AA010-81EC-4D06-9276-67AACB7B9517Q34687255-8341DD9F-B7F9-4DC9-B034-130C4432256EQ35007560-FA8456D9-6DA0-4A95-BC49-5A4501657C5CQ35449696-60FE1854-641F-4F21-B123-FB43211BAC82Q36142772-7B3D3662-DE26-4A19-85FB-3ACB14B0BE79Q36645517-9BA032C1-CB27-439B-AC57-A8D11B42D432Q36790471-E1A27AFA-61D0-4198-A1BD-1E0D02F9CCBFQ37138516-DED90175-EFFB-49CC-B7FB-480FF1E133B3Q38071386-EE0B2DF7-9A22-4742-91B9-48AA71C1AA5AQ38952060-F9E3C4B5-804C-43D4-9CED-0C2F01F79BB2Q39104518-4D1E1BCF-AD5B-4E63-BC0E-DA87775AB3DCQ40641829-D23C91FB-A4F0-4C22-9B40-D362C9FC1D69Q40994676-DCC610E7-CE8C-425E-B9D1-21F5251C6998Q41648281-FE9ED9E5-ADFF-4424-9F3E-337A9CD399D1Q41729153-7A36CECD-561C-40EA-8D63-350DF9115697Q42196934-303AE11B-D159-480F-83D4-6D59F5716C3AQ42212364-AEB565DA-BA88-4FDF-A8BF-BC951E2D4EF8Q47556299-71A12777-6D9F-4CF4-9637-6F0EBC884313
P2860
Understanding silibinin's modes of action against HCV using viral kinetic modeling
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Understanding silibinin's modes of action against HCV using viral kinetic modeling
@ast
Understanding silibinin's modes of action against HCV using viral kinetic modeling
@en
type
label
Understanding silibinin's modes of action against HCV using viral kinetic modeling
@ast
Understanding silibinin's modes of action against HCV using viral kinetic modeling
@en
prefLabel
Understanding silibinin's modes of action against HCV using viral kinetic modeling
@ast
Understanding silibinin's modes of action against HCV using viral kinetic modeling
@en
P2093
P2860
P1476
Understanding silibinin's modes of action against HCV using viral kinetic modeling
@en
P2093
Harel Dahari
Jeremie Guedj
Peter Ferenci
Ralf T Pohl
P2860
P304
P356
10.1016/J.JHEP.2011.12.012
P577
2012-01-13T00:00:00Z